Insider Trading June 26, 2026 09:40 PM

Cavco Industries CFO Aden Allison Executes Pre-arranged Sale of 1,473 Shares

Automatic transaction under Rule 10b5-1 plan reduces executive holdings; company reports Q4 fiscal 2026 results with earnings beat but revenue miss.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CVCO

Aden Allison, Executive Vice President and Chief Financial Officer of Cavco Industries, Inc. (NASDAQ:CVCO), executed a sale of 1,473 shares of company common stock on June 25, 2026. The transaction, valued at $920,625, was conducted at a fixed price of $625.00 per share and was carried out automatically under a Rule 10b5-1 trading plan adopted in November 2025. This automated execution means the sale does not reflect a discretionary decision by the executive based on current market conditions. Following the transaction, Allison retains direct ownership of 9,147 shares, which includes 2,249 shares underlying Restricted Stock Units that have been allocated but remain unvested. The trading plan has 319 shares remaining before its automatic termination on July 3, 2026. The sale occurs against the backdrop of Cavco’s recent financial reporting for the fourth quarter of fiscal year 2026, where the company posted an earnings per share (EPS) of $5.42, exceeding analyst expectations of $5.26. However, revenue fell short of projections, coming in at $550.1 million against an anticipated $571.06 million.

Cavco Industries CFO Aden Allison Executes Pre-arranged Sale of 1,473 Shares
CVCO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aden Allison sold 1,473 shares at $625.00 per share via a Rule 10b5-1 plan.
  • Post-sale, Allison holds 9,147 shares, including 2,249 unvested Restricted Stock Units.
  • Cavco reported Q4 FY2026 EPS of $5.42, beating estimates, but revenue missed at $550.1 million.

Phoenix-based Cavco Industries, Inc. (NASDAQ:CVCO) reported a significant insider transaction involving its Chief Financial Officer, Aden Allison. On June 25, 2026, Allison, who serves as Executive Vice President, Chief Financial Officer, and Treasurer, sold 1,473 shares of the company's common stock. The transaction was executed at a uniform price of $625.00 per share, resulting in a total sale value of $920,625.

Key Points

  • Automatic Execution Under Rule 10b5-1: The sale was not a discretionary move by the CFO but was executed automatically pursuant to a Rule 10b5-1 trading plan. Allison adopted this pre-arranged plan on November 26, 2025, which dictates the timing and pricing of future transactions, insulating the trade from potential insider information concerns.
  • Post-Transaction Ownership Structure: Following the sale, Allison's direct ownership in Cavco Industries stands at 9,147 shares. This figure encompasses 2,249 shares underlying Restricted Stock Units that have been allocated but have not yet vested or been delivered. The active Rule 10b5-1 trading plan retains 319 shares available for sale before it is set to terminate automatically on July 3, 2026.
  • Recent Financial Performance Context: The transaction follows Cavco's fourth-quarter fiscal year 2026 earnings report. The company delivered an EPS of $5.42, beating the consensus estimate of $5.26 by 3.04%. Despite this earnings beat, revenue fell short of the projected $571.06 million, recording $550.1 million. The earnings beat suggests operational efficiency, while the revenue miss indicates a gap between actual sales and market expectations.

At the time of the transaction, Cavco's stock was trading at $618.30. The stock has experienced a substantial surge of 43.67% over the past year, leading to a market capitalization of $4.74 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list. Conversely, the company holds more cash than debt on its balance sheet, contributing to its

Risks

  • The stock is flagged as overvalued relative to Fair Value by InvestingPro analysis.
  • Revenue shortfall in Q4 FY2026 indicates potential challenges in meeting sales projections.
  • The Rule 10b5-1 plan terminates on July 3, 2026, limiting future automated sales by Allison under this specific plan.

More from Insider Trading

Spyre Therapeutics CFO Burrows Executes $1.3M Stock Sale Amid Clinical Momentum Jun 26, 2026 Natera Legal Officer Daniel Rabinowitz Executes $8.45 Million Share Sale Under Pre-Arranged Plan Jun 26, 2026 Natera Director Herm Rosenman Offloads $4.13M in NTRA Shares Jun 26, 2026 NextNav COO Susan Insley Executes Stock Sale Under Pre-Existing Trading Plan Jun 26, 2026 ImmunityBio Director Executes $196,907 Stock Sale Under Pre-Arranged Trading Plan Jun 26, 2026